Myriad Genetics reported on Tuesday that its third quarter revenues fell 7 percent year over year primarily due to currency translations and change of estimates in diagnostic test cash collection, and non-recurring milestone payments.

In the evening of October 28, YHLO released its 2022 third quarterly report, the company achieved revenue of CNY 3.129 billion in the first three quarters of 2022, an increase of 265.06% year-on-year

Thermo Fisher Scientific said on Monday that it has reached a definitive agreement to acquire The Binding Site Group, a UK-based specialty diagnostics company, for ￡2.25 billion ($2.60 billion) in cash.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions.

Gongdong Medical Technology announced that it plans to increase the capital of its wholly owned subsidiary GD Medical with its own funds or self-raised funds of 45 million US dollars to acquire the core assets of Trademark Plastics Inc. ("TPI").

BioMérieux announced on Wednesday that its third quarter revenues rose approximately 3 percent year over year due in part to unexpectedly strong sales in its BioFire product line.

DiaSorin reported Thursday its third quarter revenues declined 5 percent year over year with waning COVID-19 testing demand, despite rising revenues across its other diagnostics businesses.

On October 20, Sansure Biotech disclosed 2022 third quarter report, the company achieved revenue of CNY 4.068 billion in three quarters this year, an increase of 24.52% year-on-year; the net profit attributable to the mother achieved CNY 1.598 billion.

Danaher on Thursday reported a 6 percent year-over-year increase in third quarter revenues as its subsidiaries see shifting demand for COVID-19-related products, such as diagnostic tests and pharmaceuticals.

Avacta, a UK-based developer of cancer immunotherapies and diagnostics, said on Tuesday that it has signed an agreement to acquire Launch Diagnostics for up to ￡37 million ($41.9 million).

Pointe Biotech (Nanjing) Co., Ltd. (hereinafter referred to as: Pointe) and its shareholders formally reached a strategic consensus and completed the signing of the contract

The company raised its earnings forecast for 2022 on estimates of $7.8 billion in annual sales related to COVID-19 testing.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.

Becton Dickinson announced on Tuesday a collaboration with Magnolia Medical Technologies, under which the firms will co-sell and comarket the Magnolia Medical Steripath and Steripath Micro Initial Specimen Diversion Device, which complement the BD Vacutainer specimen collection portfolio.

Illumina said on Tuesday that it has partnered with French company GenoScreen on genomic testing for multidrug-resistant tuberculosis.